Connor, Clark & Lunn Investment Management Ltd. Verastem, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.39 - $0.71 $98 - $179	253 Added 0.13%	188,782 $79,000
Q4 2022 Feb 10, 2023	BUY	$0.33 - $10.44 $22,166 - $701,254	67,170 Added 55.35%	188,529 $75,000
Q3 2022 Nov 10, 2022	BUY	$0.92 - $11.16 $111,650 - $1.35 Million	121,359 New	121,359 $103,000
Q2 2021 Aug 12, 2021	SELL	$2.57 - $4.85 $74,026 - $139,699	-28,804 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$1.9 - $2.82 $77,113 - $114,452	-40,586 Reduced 58.49%	28,804 $71,000
Q4 2020 Feb 16, 2021	BUY	$1.15 - $2.4 $79,798 - $166,536	69,390 New	69,390 $148,000
Q2 2018 Aug 02, 2018	SELL	$2.88 - $8.67 $530,856 - $1.6 Million	-184,325 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$2.92 - $3.81 $34,967 - $45,624	11,975 Added 6.95%	184,325 $549,000
Q4 2017 Feb 09, 2018	SELL	$2.99 - $4.85 $32,366 - $52,501	-10,825 Reduced 5.91%	172,350 $529,000
Q3 2017 Nov 14, 2017	SELL	$3.01 - $5.41 $349,009 - $627,289	-115,950 Reduced 38.76%	183,175 $861,000
Q2 2017 Aug 14, 2017	BUY	N/A	299,125	299,125 $652,000

Others Institutions Holding VSTM

# of Institutions

Shares Held

297K

Call Options Held

Put Options Held

Telemetry Investments, L.L.C. New York, NY

225K
Shares

$897,750
0.14% of portfolio
Beaumont Financial Partners, LLC

48K
Shares

$191,520
0.0% of portfolio
Eaton Vance Management Boston, MA

20K
Shares

$79,800
0.0% of portfolio
American Portfolios Advisors Holbrook, NY

2.99K
Shares

$11,910
0.0% of portfolio
Brewin Dolphin Wealth Management LTD Conskleagh, Dublin, L2

1.07K
Shares

$4,285
0.0% of portfolio

View Full List

About Verastem, Inc.

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $838M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

More about VSTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account